
## Amélie Boichard

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/209099/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Prevalence of <i>PDL1</i> Amplification and Preliminary Response to Immune Checkpoint Blockade in Solid Tumors. JAMA Oncology, 2018, 4, 1237.	7.1	214
2	Real-world data from a molecular tumor board demonstrates improved outcomes with a precision N-of-One strategy. Nature Communications, 2020, 11, 4965.	12.8	172
3	High expression of PD-1 ligands is associated with <i>kataegis</i> mutational signature and APOBEC3 alterations. Oncolmmunology, 2017, 6, e1284719.	4.6	64
4	APOBEC-related mutagenesis and neo-peptide hydrophobicity: implications for response to immunotherapy. Oncolmmunology, 2019, 8, 1550341.	4.6	60
5	Role of ultraviolet mutational signature versus tumor mutation burden in predicting response to immunotherapy. Molecular Oncology, 2020, 14, 1680-1694.	4.6	33
6	Mutated <i>TP53</i> is a marker of increased <i>VEGF</i> expression: analysis of 7,525 pan-cancer tissues. Cancer Biology and Therapy, 2020, 21, 95-100.	3.4	32
7	New therapeutic approaches to overcoming resistant EGFR exon 20 alterations. Critical Reviews in Oncology/Hematology, 2020, 151, 102990.	4.4	12
8	Machine learning model to predict oncologic outcomes for drugs in randomized clinical trials. International Journal of Cancer, 2020, 147, 2537-2549.	5.1	9
9	The Crossroads of Precision Medicine and Therapeutic Decision-Making: Use of an Analytical Computational Platform to Predict Response to Cancer Treatments. Cancers, 2020, 12, 166.	3.7	7
10	<i>BRAF</i> mutation as a novel driver of eosinophilic cystitis. Cancer Biology and Therapy, 2017, 18, 655-659.	3.4	5
11	Variable Mutation Expression in Human Cancers: A "Hide-and-Seek―Mechanism Linked to Differential MHC-I Presentation Dynamics. Molecular Cancer Therapeutics, 2022, 21, 1219-1226.	4.1	0